Clinical Characteristics and Long-Term Outcomes of Adrenal Tumors in Children and Adolescents

Abstract

Objective Adrenal tumors are generally rare in children and can be a part of familial cancer syndrome. This research was conducted to examine the clinical outcomes, histopathological results, and genetic etiologies of adrenal tumors in children and adolescents.

Methods Thirty-one children and adolescents with adrenal tumors were included. Data on clinical outcomes and endocrine and radiologic results were retrospectively analyzed. Molecular analysis was conducted in select patients according to their phenotype and family history.

Results The median age at diagnosis was 7.9 years (range: 0.8−17.8 years) with 5.1±1.8 cm of maximum tumor diameter. Adrenal adenoma (n=7), carcinoma (n=5), borderline (n=2), isolated micronodular adrenocortical disease (n=2), pheochromocytoma (n=8), paraganglioma (n=3), and ganglioneuroma (n=4) are all pathological diagnoses. The most common presenting symptom was excess production of adrenocortical hormones (n=15), including virilization and Cushing syndrome. Non-functioning adrenocortical tumors were found in a patient with congenital adrenal hyperplasia. Genetic etiologies were identified in TP53 (n=5), VHL (n=4), and PRKACA (n=1). Patients with mutations in TP53 were young (1.5±0.5 years) and had large masses (6.1±2.3 cm).

Conclusions This study describes clinical outcomes and the pathological spectrum of adrenal tumors in children and adolescents. Adrenocortical tumors mostly presented with an excess of the adrenocortical hormone. Patients with genetic defects presented at a young age and large size of tumors, necessitating genetic testing in patients at a young age.

Key words

adrenal tumor - Li Fraumeni syndrome - von Hippel-Lindau disease - pheochromocytoma

Publication History

Received: 24 February 2023
Received: 08 June 2023

Accepted: 06 July 2023

Accepted Manuscript online:
12 July 2023

Article published online:
06 September 2023

• References

• 1 Iñiguez-Ariza NM, Kohlenberg JD, Delivanis DA. et al. Clinical, biochemical, and radiological characteristics of a single-center retrospective cohort of 705 large adrenal tumors. Mayo Clinic Proc Innov Qual Outcomes 2017; 2: 30-39
• 2 Ebbehoj A, Li D, Kaur RJ. et al. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: A population-based cohort study. Lancet Diabetes Endocrinol 2020; 8: 894-902
• 3 Mansmann G, Lau J, Balk E. et al. The clinically inapparent adrenal mass: Update in diagnosis and management. Endocr Rev 2004; 25: 309-340
• 4 Pinto EM, Zambetti GP, Rodriguez-Galindo C. Pediatric adrenocortical tumours. Baillieres Best Pract Res Clin Endocrinol Metab 2020; 34: 101448
• 5 Mete O, Erickson LA, Juhlin CC. et al. Overview of the 2022 WHO classification of adrenal cortical tumors. Endocr Pathol 2022; 33: 155-196
• 6 Papotti M, Libè R, Duregon E. et al. The Weiss score and beyond—histopathology for adrenocortical carcinoma. Horm Cancer 2011; 2: 333-340
• 7 Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol 2012; 351: 66-70
• 8 Lalli E, Figueiredo BC. Pediatric adrenocortical tumors: What they can tell us on adrenal development and comparison with adult adrenal tumors. Front Endocrinol (Lausanne) 2015; 6: 23
• 9 Michalkiewicz E, Sandrini R, Figueiredo B. et al. Clinical and outcome characteristics of children with adrenocortical tumors: A report from the international pediatric adrenocortical tumor registry. J Clin Oncol 2004; 22: 838-845
• 10 Gupta N, Rivera M, Novotny P. et al. Adrenocortical carcinoma in children: A clinicopathological analysis of 41 patients at the Mayo Clinic from 1950 to 2017. Horm Res Paediatr 2018; 90: 8-18
• 11 Bholah R, Bunchman TE. Review of pediatric pheochromocytoma and paraganglioma. Front Pediatr 2017; 5: 155
• 12 Bausch B, Wellner U, Bausch D. et al. Long-term prognosis of patients with pediatric pheochromocytoma. Endocr Relat Cancer 2014; 21: 17-25
• 13 Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol 2017; 28: 213-227
• 14 Dages KN, Kohlenberg JD, Young WF. et al. Presentation and outcomes of adrenal ganglioneuromas: A cohort study and a systematic review of literature. Clin Endocrinol (Oxf) 2021; 95: 47-57
• 15 Park H, Kim M-S, Lee J. et al. Clinical presentation and treatment outcomes of children and adolescents with pheochromocytoma and paraganglioma in a single center in Korea. Front Endocrinol (Lausanne) 2021; 11: 610746
• 16 Cho MJ, Kim DY, Kim SC. et al. Adrenocortical tumors in children 18 years old and younger. J Korean Surg Soc 2012; 82: 246-250
• 17 Kang E, Cho JH, Choi J-H. et al. Etiology and therapeutic outcomes of children with gonadotropin-independent precocious puberty. Ann Pediatr Endocrinol Metab 2016; 21: 136-142
• 18 Kim SE, Lee NY, Cho WK. et al. Adrenocortical carcinoma and a sporadic MEN1 mutation in a 3-year-old girl: A case report. Ann Pediatr Endocrinol Metab 2022; 27: 315-319
• 19 Yu HW, Cho WI, Chung HR. et al. Multiple osteoblastomas in a child with Cushing syndrome due to bilateral adrenal micronodular hyperplasias. Ann Pediatr Endocrinol Metab 2016; 21: 47-50
• 20 Zarate S, Carroll A, Mahmoud M. et al. Parliament2: Accurate structural variant calling at scale. Gigascience 2020; 9 giaa145
• 21 Geoffroy V, Herenger Y, Kress A. et al. AnnotSV: An integrated tool for structural variations annotation. Bioinformatics 2018; 34: 3572-3574
• 22 Richards S, Aziz N, Bale S. et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-424
• 23 Lughezzani G, Sun M, Perrotte P. et al. The European Network for the study of adrenal tumors staging system is prognostically superior to the international union against cancer-staging system: A North American validation. Eur J Cancer 2010; 46: 713-719
• 24 Wasserman JD, Novokmet A, Eichler-Jonsson C. et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: A Children’s Oncology Group Study. J Clin Oncol 2015; 33: 602-609
• 25 Lodish MB, Yuan B, Levy I. et al. Germline PRKACA amplification causes variable phenotypes that may depend on the extent of the genomic defect: Molecular mechanisms and clinical presentations. Eur J Endocrinol 2015; 172: 803-811
• 26 Tabaro F, Minervini G, Sundus F. et al. VHLdb: A database of von Hippel-Lindau protein interactors and mutations. Sci Rep 2016; 6: 31128
• 27 Young WF. The incidentally discovered adrenal mass. N Engl J Med 2007; 356: 601-610
• 28 Zennaro M-C, Boulkroun S, Fernandes-Rosa F. Genetic causes of functional adrenocortical adenomas. Endocr Rev 2017; 38: 516-537
• 29 Brenna CTA, Michaeli O, Wasserman JD. et al. Clinical outcomes of children with adrenocortical carcinoma in the context of germline TP53 status. J Pediatr Hematol Oncol 2021; 43: e635-e641
• 30 Ishimoto H, Jaffe RB. Development and function of the human fetal adrenal cortex: A key component in the feto-placental unit. Endocr Rev 2011; 32: 317-355
• 31 Wasserman JD, Zambetti GP, Malkin D. Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol 2012; 351: 101-110
• 32 Engels M, Pijnenburg-Kleizen KJ, Utari A. et al. Glucocorticoid activity of adrenal steroid precursors in untreated patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2019; 104: 5065-5072
• 33 Nermoen I, Falhammar H. Prevalence and characteristics of adrenal tumors and myelolipomas in congenital adrenal hyperplasia: A systematic review and meta-analysis. Endocr Pract 2020; 26: 1351-1365
• 34 Fassnacht M, Johanssen S, Fenske W. et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010; 95: 4925-4932
• 35 Sandru F, Petca R-C, Carsote M. et al. Adrenocortical carcinoma: Pediatric aspects (Review). Exp Ther Med 2022; 23: 287
• 36 Pinto EM, Rodriguez-Galindo C, Pounds SB. et al. Identification of clinical and biologic correlates associated with outcome in children with adrenocortical tumors without germline TP53 mutations: A St Jude Adrenocortical Tumor Registry and Children's Oncology Group Study. J Clin Oncol 2017; 35: 3956-3963
• 37 Araujo-Castro M, Marazuela M. Cushing´s syndrome due to bilateral adrenal cortical disease: bilateral macronodular adrenal cortical disease and bilateral micronodular adrenal cortical disease. Front Endocrinol (Lausanne) 2022; 13: 913253
• 38 Horvath A, Boikos S, Giatzakis C. et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 2006; 38: 794-800
• 39 Horvath A, Mericq V, Stratakis CA. Mutation in PDE8B, a cyclic AMP–specific phosphodiesterase in adrenal hyperplasia. N Engl J Med 2008; 358: 750-752
• 40 van Berkel A, Lenders JWM, Timmers HJLM. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma. Eur J Endocrinol 2014; 170: R109-R119
• 41 Pham TH, Moir C, Thompson GB. et al. Pheochromocytoma and paraganglioma in children: A review of medical and surgical management at a tertiary care center. Pediatrics 2006; 118: 1109-1117
• 42 Fassnacht M, Assie G, Baudin E. et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN cinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 1476-1490
• 43 Parisien-La Salle S, Chbat J, Lacroix A. et al. Postoperative recurrences in patients operated for pheochromocytomas and paragangliomas: New data supporting lifelong surveillance. Cancers (Basel) 2022; 14: 2942